# FiercePharma * **Definition:** FiercePharma is a news source that provides in-depth coverage and analysis of the pharmaceutical industry, including drug development, regulatory issues, market trends, and business strategies. * **Taxonomy:** Key Sources / Healthcare Publications / FiercePharma ## News * Selected news from the source **FiercePharma**, for healthcare technology leaders * 1.2K news items are in the system for this source * Posts have been filtered for tech-related keywords | Date | Title | Topics | | --- | --- | --- | | 5/6/2025 | [**Eyeing tariffs, BMS unveils 5-year, $40B US investment - Fierce Pharma**](https://www.fiercepharma.com/pharma/now-not-time-retreat-bristol-myers-ceo-blasts-trump-admin-tariffs-health-reforms-amid-40b-us) | [[Healthcare Artificial Intelligence]]; [[Life Science]]; [[Medical Research]] | | 4/16/2025 | [**Trump throws pharma 'bread crumb' concession with call to end IRA pill penalty**](https://www.fiercepharma.com/pharma/trumps-move-end-ira-pill-penalty-lauded-industry-watchers-lawmakers-patient-groups-raise) | [[Negotiations]]; [[Drug Price Negotiation]]; [[Medicare]] | | 4/1/2025 | [**Stirred & Shaken: Navigating Potential Disruptions at the U.S. National Institutes of Health**](https://www.fiercepharma.com/premium/webinar/1369319) | [[Health]]; [[Legal Challenges]]; [[Project Management]] | | 1/14/2025 | [**AI in Clinical Trials: Simplifying the Path to Insights - Fierce Pharma**](https://www.fiercepharma.com/premium/webinar/ai-clinical-trials-simplifying-path-insights) | [[AI in Telehealth]]; [[AI-Powered Diagnostics]]; [[AI in Emergency Medicine]] | | 12/19/2024 | [**Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation**](https://www.fiercepharma.com/pharma/novartis-shutter-2-morphosys-sites-lay-330-staffers-post-buyout-consolidation) | [[Pediatric Oncology]]; [[Acquisition]]; [[Decentralized Clinical Trials]] | | 12/5/2024 | [**What's next in AI's drug discovery journey**](https://www.fiercepharma.com/sponsored/whats-next-ais-drug-discovery-journey-0) | [[Biotech]]; [[Clinical Trial Efficiency]]; [[Generative AI Applications]] | | 12/3/2024 | [**IRA price negotiations and Mopics to watch after Republican 'red wave,' analyst group says**](https://www.fiercepharma.com/pharma/medicare-drug-price-talks-insurance-coverage-and-ma-among-biopharma-interests-subject) | [[Healthcare Real Estate]]; [[Public Health]]; [[Influence]] | | 11/19/2024 | [**KnippeRx Transforms Patient Assistance Programs through Technology and Patient-Focused Solutions.**](https://www.fiercepharma.com/sponsored/knipperx-transforms-patient-assistance-programs-through-technology-and-patient-focused) | [[Financial Constraints]]; [[AI for Healthcare Providers]]; [[Automation]] | | 10/30/2024 | [**Opportunities for innovation and flexibility in mRNA and LNP manufacturing**](https://www.fiercepharma.com/sponsored/opportunities-innovation-and-flexibility-mrna-and-lnp-manufacturing) | [[Innovation]]; [[Influence]]; [[Procurement]] | | 10/25/2024 | [**2025 AI and Data Predictions for Life Sciences - Fierce Pharma**](https://www.fiercepharma.com/premium/webinar/2025-ai-and-data-predictions-life-sciences) | [[Objective Analytics]]; [[Patient Care]]; [[Regulatory Complexities]] | | 10/10/2024 | [**Vertex, nearing finish line for non-opioid drug, delves into current difficulties in pain treatment**](https://www.fiercepharma.com/marketing/vertex-nearing-finish-line-non-opioid-drug-delves-current-difficulties-pain-treatment) | [[AI in Healthcare]]; [[Pain Treatment]]; [[Healthcare Providers]] | | 10/7/2024 | [**What's the Impact of Data Modernization and AI on Precision Medicine?**](https://www.fiercepharma.com/sponsored/whats-impact-data-modernization-and-ai-precision-medicine) | [[Regulatory Challenges]]; [[Healthcare]]; [[Regulatory Complexities]] | | 9/25/2024 | [**Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta**](https://www.fiercepharma.com/pharma/pfizer-issues-global-market-withdrawal-sickle-cell-disease-therapy-oxbryta) | [[Patient Safety Risks]]; [[Healthcare Education]]; [[Healthcare Legislation]] | | 9/19/2024 | [**AstraZeneca's vision for the future of respiratory care**](https://www.fiercepharma.com/sponsored/astrazenecas-vision-future-respiratory-care) | [[Patient Engagement Solutions]]; [[AI-Driven Tools]]; [[Digital Health Platforms]] | | 9/18/2024 | [**Optimizing Patient Support Through Effective Information Governance: Balancing Risks and Rewards**](https://www.fiercepharma.com/sponsored/optimizing-patient-support-through-effective-information-governance-balancing-risks-and) | [[Healthcare Education]]; [[Governance]]; [[Data Integrity Issues]] | | 9/11/2024 | [**KEY STEPS IN THE VACCINE SCALE-UP JOURNEY - Fierce Pharma**](https://www.fiercepharma.com/premium/webinar/key-steps-vaccine-scale-journey) | [[Infectious Disease]]; [[Collaboration]]; [[Partnerships]] | | 9/10/2024 | [**After BIOSECURE Act passes in House, targeted Chinese companies say they're 'deeply' concerned**](https://www.fiercepharma.com/pharma/china-focused-biosecure-act-passes-house-heres-what-targeted-companies-are-saying) | [[Marketing]]; [[Genome Editing]]; [[Security Concerns]] | | 9/9/2024 | [**Peter Lee - Fierce Pharma**](https://www.fiercepharma.com/pharma/peter-lee?itm_source=parsely-api) | [[Digital Health Solutions]]; [[AI in Clinical Trials]]; [[AI Implementation Challenges]] | | 9/9/2024 | [**Peter Lee - Fierce Pharma**](https://www.fiercepharma.com/pharma/peter-lee) | [[Healthcare Operations]]; [[Private Equity in Healthcare]]; [[Genomics]] | | 9/5/2024 | [**BIOSECURE Act heads for possible vote in House of Representatives next week**](https://www.fiercepharma.com/pharma/china-targeting-biosecure-act-headed-house-vote-next-week) | [[Medicaid Cuts]]; [[Biopharma]]; [[Medicare]] | | 8/29/2024 | [**IRA biosimilar measure intended to boost uptake so far has 'limited' impact: report**](https://www.fiercepharma.com/pharma/ira-biosimilar-policy-meant-boost-uptake-so-far-has-limited-impact-report) | [[Surgical Oncology]]; [[Population Health]]; [[Access to Treatments]] | | 8/23/2024 | [**What Chevron's overturn means for biopharma**](https://www.fiercepharma.com/pharma/what-chevrons-overturn-means-biopharma) | [[Healthcare]]; [[Connected Drug Delivery Devices]]; [[Vaccine Development]] | | 8/21/2024 | [**Sustainability is increasingly important in pharma, but several hurdles are slowing the effort: survey**](https://www.fiercepharma.com/pharma/cytiva-exec-survey-highlights-importance-sustainability-and-difficulties-achieving-it) | [[Cost Barriers]]; [[Biotech]]; [[Business Goals]] | | 8/20/2024 | [**Lawmakers urge FDA to investigate clinical trials run in tandem with China's military**](https://www.fiercepharma.com/pharma/amid-biosecure-brouhaha-house-committee-urges-fda-investigate-clinical-trials-run-tandem) | [[Bioinformatics]]; [[Hospitals]]; [[Decentralized Clinical Trials]] | | 8/19/2024 | [**Genmab shuffles C-Suite on commercialization, manufacturing as portfolio grows**](https://www.fiercepharma.com/pharma/genmab-shuffles-c-suite-commercialization-manufacturing-portfolio-grows) | [[Healthtech]]; [[Executive Team]]; [[Leadership Changes]] | ## Recent Stories (Some LLM-derived content — please confirm with above primary sources) ### Topics Covered - **Ramarketing**: Enhancing AI technologies for client marketing strategies, with new appointments in data and delivery roles. - **Agilent Technologies**: Acquisition of Canadian CDMO Biovectra for $925 million to boost contract manufacturing capabilities. - **Clinigen**: Acquisition of Kinesys Consulting to enhance regulatory affairs services. - **Johnson & Johnson**: New rebate model for drugs Stelara and Xarelto in response to Medicare drug price negotiations. - **Pfizer**: Launch of PfizerForAll platform to connect patients with healthcare services directly. - **Deloitte Survey**: C-suite executives optimistic about 2025 despite inflation and supply chain concerns. - **Eli Lilly**: Expansion in India with a new global capability center in Hyderabad. - **Radiopharmaceutical Acquisitions**: Major companies investing over $8 billion in radiopharmaceutical firms. - **Teva Pharmaceuticals**: Lawsuit against CMS regarding Medicare drug price negotiations. - **Bharat Biotech**: Expansion into advanced therapeutics with a new cell and gene therapy facility. - **2024 Presidential Election**: Intensifying race between President Biden and former President Trump, focusing on drug pricing strategies. - **AstraZeneca Stock Drop**: 8.4% decline due to concerns over a potential insurance fraud investigation in China. - **Accord Healthcare**: Expanding its Fawdon manufacturing facility with a £50 million investment from the UK government. - **Reata Pharmaceuticals**: Successful launch of Skyclarys for Friedreich's ataxia, leading to Biogen's acquisition. - **GSK**: Decided not to renew membership with BIO, following a trend of exits by other companies. - **GenScript**: Establishing a new operations center in Sydney amid a U.S. investigation into its ties with the Chinese Communist Party. - **Pharma Patient Assistance Programs**: KnippeRx innovating to improve efficiency and patient experience in medication access. - **GoodRx**: Focusing on medication affordability and access, addressing rising healthcare costs for patients. - **ALS Market Growth**: The ALS market is projected to grow to nearly $1.3 billion by 2029, driven by a 15% annual growth rate, with unmet needs in early diagnosis and disease-modifying therapies. - **WuXi Companies and BIOSECURE Act**: WuXi AppTec and WuXi Biologics saw a temporary increase in share prices amid concerns about the BIOSECURE Act, which could restrict U.S. drugmakers' ties with foreign biotech firms. ### Organizations Mentioned - **Ramarketing**: A U.K.-based life sciences marketing agency. - **Agilent Technologies**: A company specializing in diagnostics and genomics. - **Clinigen**: A London-based biopharma services company. - **Johnson & Johnson**: A multinational corporation in the pharmaceutical and consumer goods sector. - **Pfizer**: A global pharmaceutical corporation. - **Deloitte**: A multinational professional services network. - **Eli Lilly**: A global pharmaceutical company. - **Teva Pharmaceuticals**: An Israeli multinational pharmaceutical company. - **Bharat Biotech**: An Indian vaccine developer. - **Biovectra**: A Canadian contract development and manufacturing organization. - **Kinesys Consulting**: A regulatory affairs specialist. - **Association for Accessible Medicines (AAM)**: An organization advocating for access to affordable medicines. - **AstraZeneca**: A multinational pharmaceutical and biotechnology company focused on drug development. - **American Lung Association**: A non-profit organization dedicated to improving lung health and preventing lung disease. - **Biogen**: A biotechnology company specializing in therapies for neurological diseases. - **GSK**: A British multinational pharmaceutical company focused on research and development of medicines and vaccines. - **GenScript**: A biotechnology company providing gene synthesis and related services. - **KnippeRx**: A company focused on improving patient assistance programs through technology. - **GoodRx**: A healthcare platform aimed at improving medication affordability and access.